08:00 , Jan 24, 2011 |  BC Week In Review  |  Clinical News

LOR-253: Phase I started

Lorus began an open-label, dose-escalation, U.S. Phase I trial to evaluate LOR-253 in up to 47 patients. Lorus Therapeutics Inc. (TSX:LOR; Pink:LRUSF), Toronto, Ontario   Product: LOR-253 (formerly LT-253 )   Business: Cancer   Molecular...